SCYNEXIS, Inc. (LON:0L49)

Market Cap	19.67M
Revenue (ttm)	2.04M
Net Income (ttm)	-20.97M
Shares Out	n/a
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,657
Average Volume	3,764
Open	0.7400
Previous Close	0.7595
Day's Range	0.7400 - 0.7700
52-Week Range	0.7150 - 2.2890
Beta	n/a
RSI	34.08
Earnings Date	Aug 14, 2025

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has lic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L49

Financial Performance

Financial numbers in USD